Tech Company Financing Transactions
Verastem Funding Round
Verastem closed a $75 million funding round on 4/25/2025. Investors included RTW Investments, BVF Partners and Nantahala Capital Management.
Transaction Overview
Company Name
Announced On
4/25/2025
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds from the financing are expected to fund the potential launch of avutometinib and defactinib in recurrent low-grade serous ovarian cancer, continued clinical research and development of product candidates including VS-7375, and for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
117 Kendrick St. 500
Needham, MA 02494
USA
Needham, MA 02494
USA
Phone
Website
Email Address
Overview
Verastem, Inc. (NASDAQ: VSTM) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Forrester
Chief Financial Officer
Robert Gagnon
Chief Operating Officer
Daniel Paterson
Chief Scientific Officer
Jonathan Pachter
VP - Bus. Development
Steven Bloom
VP - Bus. Development
Joseph Lobacki
VP - Bus. Development
Nadeem Mirza
VP - General Counsel
Sean Flynn
VP - Human Resources
Cathy Carew
Browse more venture capital transactions:
Prev: 4/25/2025: Jericho Security venture capital transaction
Next: 4/25/2025: Deferred venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs